含铂两药联合化疗对老年晚期非小细胞肺癌的临床分析  

Clinical analysis of platinum-based doublet chemotherapy for elderly patients with advanced non-small cell lung cancer

作　　者：张淑立[1] 王毅[1] 刘学东[1] 葛云洁[1] 

机构地区：[1]青岛市市立医院呼吸科,山东青岛266011

出　　处：《中国医药科学》2013年第21期79-80,108,共3页China Medicine And Pharmacy

摘　　要：目的评价含铂两药联合化疗对老年晚期非小细胞肺癌的疗效及安全性。方法回顾分析60例年龄≥70岁、经病理确诊的晚期非小细胞肺癌患者，根据病理类型，鳞癌一线采用顺铂联合吉西他滨，非鳞癌采用顺铂联合培美曲塞，顺铂25mg／m2，dl～3，吉西他滨1000mg／m2，dl，8，培美曲塞500mglm。，dl，21d为1个周期。结果60例患者均可评价疗效及不良反应。CR0例，PR20例，SD28例，PD12例，客观有效率为33．3％，疾病控制率为80％，中位无疾病进展时间为7．3个月，主要不良反应为乏力、白细胞下降、贫血、血小板下降、恶心、呕吐及便秘，未出现与化疗相关的死亡。结论对于Ps评分好的老年人，含铂两药联合化疗对晚期非小细胞肺癌疗效确切、可靠，安全性较好，不良反应可耐受。Objective To evaluate the efficacy and safety of platinum-based doublet chemotherapy for aged patients with advanced non-small cell lung cancer. Methods 60 aged patients（age 〉 70） with advanced non-small cell lung cancer were retrospectively analyzed. As for squamous lung cancer, the first-line treatment was gemcitabine plus cisplatin, and for nonsquamous lung cancer was pemetrexed plus eisplatin, ervery 3 weeks. Results The efficacy and side effects were evaluated for all 60 patients. There were 0 case of CR, 20 cases of PR, 28 cases of SD and 12 cases of PD. The effective rate was 33.3%, disease control rate was 80%, progression free survival was 7.3 months, and main side effects included anergy, leucopenia, anemia, thrombopenia and emesis, without deaths. Conclusion The efficacy and safety of platinum-based doublet chemotherapy for aged patients with advanced non-small cell lung cancer were good and reliable, without unacceptable side effects.

关 键 词：含铂两药 联合化疗 老年人 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]